Dinutuximab beta in high-risk neuroblastoma: a profile of its use
- 125 Downloads
Dinutuximab beta (Qarziba®), a monoclonal antibody, is indicated to treat high-risk neuroblastoma in patients aged ≥ 12 months in the first-line setting subsequent to front-line treatment with induction chemotherapy, myeloablative therapy and stem cell transplantation (SCT), as well as in the relapsed/refractory setting. It targets disialoganglioside 2, which is highly expressed on neuroblastoma cells. Unlike dinutuximab, which is produced using mouse SP2/0 cells, dinutuximab beta is produced using the more widely used Chinese hamster ovary cells. In both the first-line and relapsed/refractory settings, treatment with dinutuximab beta achieves objective clinical responses in patients with high-risk neuroblastoma. Following standard front-line treatment, survival rates were higher in dinutuximab beta recipients than in historical controls treated in the pre-immunotherapy era. Appropriate measures should be taken to manage toxicities (e.g. neuropathic pain, pyrexia and hypersensitivity reactions) associated with dinutuximab beta treatment. The continuous, 10-day infusion regimen appears to be associated with less toxicity than the once-daily infusion on 5 consecutive days.
The manuscript was reviewed by: P.F. Ambros, Children’s Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; F.H. Felix, Pediatric Cancer Center, Hospital Infantil Albert Sabin, Fortaleza, Brazil; R. Kebudi, Division of Pediatric Hematology-Oncology, Cerrahpaşa Medical Faculty & Oncology Institute, Istanbul, Turkey; H.B. Lindsay, Pediatric Hematology/Oncology, Baylor College of Medicine, Houston, TX, USA; J. Morales, Pharmacy Department, Hospital Dr Luis Calvo Mackenna, Santiago, Chile. During the peer review process, EUSA Pharma (UK) Limited, the marketing-authorization holder of dinutuximab beta, was offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made on the basis of scientific and editorial merit.
The preparation of this review was not supported by any external funding.
Compliance with ethical standards
Conflict of interest
K McKeage and K.A. Lyseng-Williamson are employees of Adis/Springer, are responsible for the article content and declare no conflicts of interest.
- 1.European Medicines Agency Committee for Medicinal Products for Human Use. Assessment report: dinutuximab beta Apeiron. London: European Medicines Agency; 2017.Google Scholar
- 7.Qarziba® (dinutuximab beta EUSA) 4.5 mg/mL concentrate for solution for infusion: summary of product characteristics. London: European Medicines Agency; 2018.Google Scholar
- 11.Ladenstein R, Pötschger U, Valteau Couanet D, et al. Immunotherapy with anti-GD2 antibody ch14.18/CHO ± IL2 within the HR-NBL1/SIOPEN trial improves outcome of high-risk neuroblastoma patients compared to historical controls [abstract]. In: Advances in Neuroblastoma Research Meeting. 2018.Google Scholar